(Q33920539)

30 July 2017

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial (English)

1 reference

30 July 2017

1 reference

hepatocellular carcinoma

1 reference

T Takayama

1

1 reference

30 July 2017

T Sekine

2

1 reference

30 July 2017

M Makuuchi

3

1 reference

30 July 2017

S Yamasaki

4

1 reference

30 July 2017

T Kosuge

5

1 reference

30 July 2017

J Yamamoto

6

1 reference

30 July 2017

K Shimada

7

1 reference

30 July 2017

M Sakamoto

8

1 reference

30 July 2017

S Hirohashi

9

1 reference

30 July 2017

Y Ohashi

10

1 reference

30 July 2017

T Kakizoe

11

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

30 July 2017

1 reference

30 July 2017

356

1 reference

30 July 2017

802-807

1 reference

30 July 2017

9232

1 reference

30 July 2017

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Early hepatocellular carcinoma as an entity with a high rate of surgical cure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Hepatic resection for hepatocellular carcinoma. An audit of 343 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Recurrence of hepatocellular carcinoma after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

An analysis of 412 cases of hepatocellular carcinoma at a Western center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Surgery for small liver cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Cytotoxic activity of CD4+ T cells against autologous tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Adjuvant adoptive immunotherapy against hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Current status of adoptive immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Clinical promise of tumour immunology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Hepatocellular carcinoma: Recent progress

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Expression of class I and class II major histocompatibility antigens on human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902654-4

7 January 2021

10.1016/S0140-6736(00)02654-4

Identifiers

DOI

1 reference

30 July 2017

1 reference